Accuracy of Image-guided Tru-cut biopsy in the diagnosis of breast tumors

Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-01 DOI:10.1016/j.ctarc.2025.100955

Alya A. Al Zobair , Wahda M. Al-Nauimy , Sabruldeen M. Mohammed

{"title":"Accuracy of Image-guided Tru-cut biopsy in the diagnosis of breast tumors","authors":"Alya A. Al Zobair , Wahda M. Al-Nauimy , Sabruldeen M. Mohammed","doi":"10.1016/j.ctarc.2025.100955","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Histopathological examination is the gold standard for the diagnosis of breast cancer. This study aims to ascertain the extent to which image-guided Tru-cut biopsy is sensitive and accurate in the diagnosis of breast cancer cases in our locality.</div></div><div><h3>Method</h3><div>This prospective study included 115 patients who presented with one or more breast lumps and suspected to be neoplastic based on the clinical and radiological assessment. All patients have been subjected to Tru-cut biopsy under ultrasound guidance to confirm or exclude the diagnosis of breast tumor, the study was conducted between January 2022 and January 2024</div></div><div><h3>Result</h3><div>Tru-cut biopsy under ultrasound-guidance has shown a high sensitivity and specificity, 98 % and 100 % respectively. Breast carcinoma was confirmed in 106 cases, while benign breast lesions were diagnosed in the remaining nine cases.</div></div><div><h3>Conclusion</h3><div>A Tru-cut biopsy of palpable breast tumors yields comprehensive information with a high sensitivity and specificity, making it a highly reliable diagnostic tool for breast tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100955"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000917","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Histopathological examination is the gold standard for the diagnosis of breast cancer. This study aims to ascertain the extent to which image-guided Tru-cut biopsy is sensitive and accurate in the diagnosis of breast cancer cases in our locality.

Method

This prospective study included 115 patients who presented with one or more breast lumps and suspected to be neoplastic based on the clinical and radiological assessment. All patients have been subjected to Tru-cut biopsy under ultrasound guidance to confirm or exclude the diagnosis of breast tumor, the study was conducted between January 2022 and January 2024

Result

Tru-cut biopsy under ultrasound-guidance has shown a high sensitivity and specificity, 98 % and 100 % respectively. Breast carcinoma was confirmed in 106 cases, while benign breast lesions were diagnosed in the remaining nine cases.

Conclusion

A Tru-cut biopsy of palpable breast tumors yields comprehensive information with a high sensitivity and specificity, making it a highly reliable diagnostic tool for breast tumors.

查看原文本刊更多论文

影像引导真切活检在乳腺肿瘤诊断中的准确性

背景：组织病理学检查是诊断乳腺癌的金标准。本研究旨在确定在何种程度上图像引导真切活检是敏感和准确的诊断乳腺癌病例在我们的地方。方法本前瞻性研究纳入115例经临床及影像学评估怀疑为肿瘤的乳房肿块患者。所有患者均在2022年1月至2024年1月期间行超声引导下的truc -cut活检以确诊或排除乳腺肿瘤，结果超声引导下的truc -cut活检具有较高的灵敏度和特异性，分别为98%和100%。106例确诊为乳腺癌，其余9例确诊为乳腺良性病变。结论乳腺可触及肿瘤的真切活检信息全面，灵敏度和特异性高，是一种高度可靠的乳腺肿瘤诊断工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.